Key result
Selective aldosterone synthase inhibitors lower office SBP by ~8 mm Hg versus placebo.
Why the study?
Existing meta-analyses of selective aldosterone synthase inhibitors for resistant and uncontrolled hypertension have included nonselective agents or omitted the latest phase 3 data.
Do selective aldosterone synthase inhibitors reduce blood pressure in patients with uncontrolled hypertension?
Meta-Analysis (n=2,856)
Yes
Do selective aldosterone synthase inhibitors reduce blood pressure in patients with uncontrolled hypertension?
Mean Difference: -8.22 (95% CI -9.43–-7)
Selective aldosterone synthase inhibitors significantly reduce office and ambulatory blood pressure in uncontrolled hypertension but are associated with dose-dependent risks of hyperkalemia, hyponatremia, and reduced eGFR.
Supports selective ASIs for resistant hypertension; extends prior meta-analyses with latest phase 3 RCT data.
Selective aldosterone synthase inhibitors (ASIs), including baxdrostat and lorundrostat, target CYP11B2 while sparing cortisol synthesis, offering a novel strategy for resistant and uncontrolled hypertension. Yet existing meta-analyses have included nonselective agents or omitted the latest phase 3 data. We searched PubMed, Scopus, Cochrane, and Web of Science from inception to March 7, 2026, for randomized controlled trials of selective ASIs versus placebo. Random-effects dose-level network meta-analyses were performed for 16 efficacy and safety outcomes. Trial sequential analysis assessed evidence firmness, and certainty was rated using the GRADE CINeMA framework. Six randomized controlled trials (2856 patients across 30 countries) were included. ASIs reduced office systolic blood pressure versus placebo [mean difference (MD) -8.22 mm Hg; 95% CI, -9.43 to -7.00; I2 = 0%]. Baxdrostat 2 mg achieved the greatest reductions in office systolic blood pressure (-10.24 mm Hg), office diastolic blood pressure (-4.40 mm Hg), and ambulatory systolic blood pressure (-14.53 mm Hg). ASIs lowered serum aldosterone and raised plasma renin activity. Safety signals included reduced eGFR (MD -6.91 mL/min/1.73 m2), hyperkalemia [risk ratio (RR) 5.04], hyponatremia (RR 2.11), and symptomatic hypotension (RR 3.17), with dose-dependent risks most pronounced for lorundrostat 100 mg.
No takes yet. Share an insight, caveat, or question.
Hammad et al. (2026) conducted a meta-analysis in resistant and uncontrolled hypertension (n=2,856). Selective aldosterone synthase inhibitors vs. placebo was evaluated on office systolic blood pressure (MD -8.22, 95% CI -9.43 to -7.00). Selective aldosterone synthase inhibitors reduced office systolic blood pressure compared to placebo (MD -8.22 mm Hg; 95% CI, -9.43 to -7.00).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: